Paul L Prather

List of Publications by Year
in descending order

41 papers	1,221 citations	516215 16 h-index	360668 35 g-index
41 all docs	41 docs citations	41 times ranked	1252 citing authors

#	Article	IF	Citations
1	Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors. Toxicological Sciences, 2022, 187, 175-185.	1.4	4
2	Non-Canonical Cannabinoid Receptors with Distinct Binding and Signaling Properties in Prostate and Other Cancer Cell Types Mediate Cell Death. International Journal of Molecular Sciences, 2022, 23, 3049.	1.8	1
3	Synthesis, Molecular Pharmacology, and Structureâ€“Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists. Journal of Medicinal Chemistry, 2021, 64, 6381-6396.	2.9	12
4	Major Metabolites of the Synthetic Cannabinoid 5Fâ€ADB Retain High Affinity and Full Efficacy at CB1 Receptors; Potential Mechanism Contributing to Enhanced Toxicity?. FASEB Journal, 2021, 35, .	0.2	0
5	Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development. Life Sciences, 2021, 285, 119993.	2.0	1
6	7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127501.	1.0	4
7	Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands. ACS Chemical Neuroscience, 2020, 11, 3455-3463.	1.7	15
8	Significance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics. Molecules, 2020, 25, 4820.	1.7	2
9	Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity. Pharmacology Biochemistry and Behavior, 2020, 195, 172949.	1.3	15
10	Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid Nâ€(adamantanâ€1â€yl)â€1â€(5â€fluoropentyl)â€1Hâ€indoleâ€3â€carboxamide (STSâ€135). Pharmacology Research and Perspectives, 2020, 8, e00561.	1.1	2
11	Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Proteinâ€“Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with Î”⁹-Tetrahydrocannabinol and JWH-018. Journal of Pharmacology and Experimental Therapeutics, 2019, 369, 259-269.	1.3	4
12	Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22). Xenobiotica, 2019, 49, 1388-1395.	0.5	3
13	Preface to DMR special edition â€˜Cannabinoid receptors and ligands: therapeutic drug development and abuse potentialâ€™. Drug Metabolism Reviews, 2018, 50, 1-2.	1.5	8
14	Pinprick hypo- and hyperalgesia in diabetic rats: Can diet content affect experimental outcome?. Neuroscience Letters, 2018, 673, 24-27.	1.0	2
15	Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants. Biochemical and Biophysical Research Communications, 2018, 498, 597-602.	1.0	24
16	Preclinical assessment of utility of M6S for multimodal acute and chronic pain treatment in diabetic neuropathy. Life Sciences, 2018, 192, 151-159.	2.0	6
17	Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Î”9-THC. Frontiers in Pharmacology, 2018, 9, 1084.	1.6	20
18	The tamoxifen derivative ridaifen-B is a high affinity selective CB 2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects. Toxicology and Applied Pharmacology, 2018, 353, 31-42.	1.3	8

#	Article	IF	Citations
19	In vitro and In vivo Effects of Phase 1 Hydroxylated Metabolites of the Synthetic Cannabinoid ABâ€PINACA [(S)â€Nâ€(1â€aminoâ€3â€methylâ€1â€oxobutanâ€2â€yl)â€1â€pentylâ€1Hâ€indazoleâ€3â€carboxamide]. FASEB Journa 825.1.	0.2	0
20	Synthetic Pot: Not Your Grandfatherâ€™s Marijuana. Trends in Pharmacological Sciences, 2017, 38, 257-276.	4.0	78
21	The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice. British Journal of Pharmacology, 2017, 174, 4523-4539.	2.7	19
22	Characterization of structurally novel G protein biased CB 1 agonists: Implications for drug development. Pharmacological Research, 2017, 125, 161-177.	3.1	32
23	Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development. PLoS ONE, 2016, 11, e0167240.	1.1	10
24	Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity. Frontiers in Pharmacology, 2016, 7, 503.	1.6	20
25	Antinociceptive effects of the 6- O -sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors. Pharmacological Research, 2016, 113, 335-347.	3.1	21
26	Non-Selective Cannabinoid Receptor Antagonists, Hinokiresinols Reduce Infiltration of Microglia/Macrophages into Ischemic Brain Lesions in Rat via Modulating 2-Arachidonolyglycerol-Induced Migration and Mitochondrial Activity. PLoS ONE, 2015, 10, e0141600.	1.1	7
27	The K2/Spice Phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metabolism Reviews, 2014, 46, 72-85.	1.5	102
28	Palmitoylethanolamide Regulates Development of Intestinal Radiation Injury in a Mast Cell-Dependent Manner. Digestive Diseases and Sciences, 2014, 59, 2693-2703.	1.1	21
29	Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Î”9-THC: Mechanism underlying greater toxicity?. Life Sciences, 2014, 97, 45-54.	2.0	236
30	Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs. European Journal of Pharmacology, 2014, 737, 140-148.	1.7	13
31	Functional consequences of synthetic cannabinoid metabolites and CYP2C9 polymorphisms (838.4). FASEB Journal, 2014, 28, 838.4.	0.2	0
32	CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen. Biochemical and Biophysical Research Communications, 2013, 441, 339-343.	1.0	21
33	Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicology and Applied Pharmacology, 2013, 269, 100-108.	1.3	78
34	Tolerance and crossâ€tolerance among highâ€efficacy synthetic cannabinoids JWHâ€018 and JWHâ€073 and lowâ€efficacy phytocannabinoid Î” 9 â€THC. FASEB Journal, 2013, 27, 1097.1.	0.2	1
35	Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochemical Pharmacology, 2012, 83, 952-961.	2.0	143
36	The omega and omegaâ€1 monohydroxyl metabolites of the abused K2/Spice synthetic cannabinoids JWHâ€018 and JWHâ€073 bind with high affinity and act as agonists at human cannabinoid 2 receptors (hCB2s). FASEB Journal, 2012, 26, 660.8.	0.2	0

#	Article	IF	Citations
37	Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity. PLoS ONE, 2011, 6, e21917.	1.1	192
38	Human UDPâ€glucuronosyltransferases (UGTs) are involved in the metabolism of the natural resveratrol analogues arachidinâ€1, arachidinâ€3 and piceatannol. FASEB Journal, 2010, 24, 967.12.	0.2	1
39	Gambogic acid binds to human CB2 receptors and exhibits potential partial agonist activity. FASEB Journal, 2010, 24, 769.1.	0.2	0
40	The Endocannabinoid Noladin Ether Acts as a Full Agonist at Human CB2 Cannabinoid Receptors. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 868-875.	1.3	74
41	Inverse Agonists: Tools to Reveal Ligand-Specific Conformations of G Protein-Coupled Receptors. Science Signaling, 2004, 2004, pe1-pe1.	1.6	19